Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756948 | 0.91 | AR (0.33) | AR | |
| SCHEMBL16160949 | 0.84 | BRD4 (0.35) | EGFRSPHK1 | |
| SCHEMBL16160933 | 0.83 | EGFR (0.35) | EGFRSPHK1 | |
| SCHEMBL16160962 | 0.82 | EGFR (0.36) | EGFRSPHK1 | |
| SCHEMBL6748055 | 0.79 | CYP2D6 (0.39) | SPHK1 | |
| SCHEMBL6748053 | 0.79 | CYP2D6 (0.39) | SPHK1 | |
| SCHEMBL16160961 | 0.78 | GPR119 (0.33) | — | |
| SCHEMBL16160928 | 0.77 | EGFR (0.34) | EGFRARSPHK1 | |
| SCHEMBL16160965 | 0.76 | BRD4 (0.34) | SPHK1 | |
| SCHEMBL16160948 | 0.76 | SPHK1 (0.38) | SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | EGFR 1409/4885AR 4016/4885SPHK1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.